Slow uptake on the trial could be a sign of lack of confidence in the drug. With no news for many months, it might be wise to steer clear of the likely decline in sp.
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
